Tailored vaccines targeting the elderly using whole inactivated influenza vaccines bearing cytokine immunomodulators

Journal of Interferon and Cytokine Research

Volumn 34, Issue 2, 2014, Pages 129-139

  Khan, Tila ^a   Heffron, Connie L ^a   High, Kevin P ^b   Roberts, Paul C ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGING; ANIMALS; HUMANS; IMMUNITY, ACTIVE; IMMUNOMODULATION; INDIVIDUALIZED MEDICINE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INFLUENZAVIRUS A; INTERLEUKIN-12; MASS VACCINATION; MICE; MICE, INBRED BALB C; POPULATION GROUPS; TRANSGENES; VIRION;

EID: 84893976640     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0119     Document Type: Article

References (41)

1. Buchanan JM, Vogel LA, Van Cleave VH, Metzger DW. 1995. Interleukin 12 alters the isotype-restricted antibody response of mice to hen eggwhite lysozyme. Int Immunol 7(9):1519-1528.
2. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A. 2012. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One 7(1):e30898.
3. Budimir N, Meijerhof T, Wilschut J, Huckriede A, de Haan A. 2010. The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenzaspecific cytotoxic T lymphocytes. Vaccine 28(52):8280-8287.
4. Cate TR, Rayford Y, Nino D, Winokur P, Brady R, Belshe R, Chen W, Atmar RL, Couch RB. 2010. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 28(9):2076-2079.
5. Centers for Disease Control and Prevention. July 31, 2009. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. Morb. Mort. Wkly Reports, (RR08), pp1-52.
6. Chakrabarti R, Chang YG, Song K, Prud'homme GJ. 2004. Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA). Vaccine 22(9-10):1199-1205. (Pubitemid 38296663)
7. Derhovanessian EPG. 2011. Vaccination in the elderly. Microb Biotechnol 5(2):226-232.
8. Durali D, de Goer de Herve MG, Giron-Michel J, Azzarone B, Delfraissy JF, Taoufik Y. 2003. In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. Blood 102(12):4084-4089. (Pubitemid 37486992)
9. Ennis FA, Meager A, Beare AS, Qi YH, Riley D, Schwarz G, Schild GC, Rook AH. 1981. Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet 2(8252):891-893. (Pubitemid 11008427)
10. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. 2009. Randomized, doubleblind controlled phase 3 trial comparing the immunogenicity of high dose and standard dose influenza vaccine in adults 65 years of age and older. J Infect Dis 200(2):172-180.
11. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. 2005. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 294(21):2712-2719. (Pubitemid 41770100)
12. Germann T, Rude E, Schmitt E. 1995. The influence of IL12 on the development of Th1 and Th2 cells and its adjuvant effect for humoral immune responses. Res Immunol 146(7-8):481-486. (Pubitemid 26054841)
13. Goodwin K, Viboud C, Simonsen L. 2006. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24(8):1159-1169. (Pubitemid 43202262)
14. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. 1995. The efficacy of influenza vaccine in elderly persons: a metaanalysis and review of the literature. Ann Intern Med 123(7):518-527.
15. Herbert AS, Heffron L, Sundick R, Roberts PC. 2009. Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge. Virol J 6:42.
16. High K. 2007. Immunizations in older adults. Clin Geriatr Med 23(3):669-685, viii-ix. (Pubitemid 47042347)
17. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. 2007. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 18(2):CD001269.
18. Katz JM, Lu XH, Todd CW, Newman MJ. 2000. A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. Vaccine 18(21):2177-2187. (Pubitemid 30136356)
19. Khan T. 2012. Tailored influenza virus vaccines for both the young and old: vaccine efficacy of whole inactivated vaccines bearing immunomodulatory adjuvants or multimeric peptides. PhD Thesis. In: Biomedical Sciences and Pathobiology. Blacksburg, Virginia: Virginia Polytechnic Institute and State University. pp 1-169.
20. Martin MD, Seth S, Koutsonanos DG, Jacob J, Compans RW, Skountzou I. 2010. Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. PLoS One 5(5):e10897.
21. McElhaney JE, Beattie BL, Devine R, Grynoch R, Toth EL, Bleackley RC. 1990. Age-related decline in interleukin 2 production in response to influenza vaccine. J Am Geriatr Soc 38(6):652-658. (Pubitemid 20212504)
22. McElhaney JE, Effros RB. 2009. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol 21(4):418-424.
23. McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. 2012. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 30(12):2060-2067.
24. Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. 2007. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25(27):5086-5096. (Pubitemid 46879994)
25. Nations U. 2009. World population ageing 2009. division. DoEaSaP, ed. United Nations, New York.
26. Naume B, Gately M, Espevik T. 1992. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56 +NK cells. J Immunol 148(8):2429-2436.
27. Nichol KL, Margolis KL, Wuorenma J, Vonsternberg T. 1994. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331(12):778-784. (Pubitemid 24284768)
28. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent end points. Am J Hyg 27:493-497.
29. Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di Pietrantonj C, Demicheli V. 2006. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev (3):CD004876.
30. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Herrmann SH, Ritz J. 1992. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175(3):779-788.
31. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng N-Y, Nishtala M, Wrammert J, Smith K, James JA, Dekker CL, Davis MM, Wilson PC, Greenberg HB, He X-S. 2011. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 121(8):3109-3119.
32. Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. 2010. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 28(38):6145-6151.
33. Siegel JP, Puri RK. 1991. Interleukin-2 toxicity. J Clin Oncol 9(4):694-704.
34. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. 2006. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55(RR-10):1-42.
35. Sullivan SJ, Jacobson R, Poland GA. 2010. Advances in the vaccination of the elderly against influenza: role of a highdose vaccine. Expert Rev Vaccines 9(10):1127-1133.
36. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2):179-186. (Pubitemid 36068705)
37. Vogel LA, Showe LC, Lester TL, McNutt RM, Van Cleave VH, Metzger DW. 1996. Direct binding of IL-12 to human and murine B lymphocytes. Int Immunol 8(12):1955-1962. (Pubitemid 27007746)
38. Weinberg A, Song LY, Walker R, Allende M, Fenton T, Patterson-Bartlett J, Nachman S, Kemble G, Yi TT, Defechereux P, Wara D, Read JS, Levin M. 2010. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 55(2):189-196.
39. Wilshut JC, McElhaney JE, Palache AM. 2006. Influenza. Philadelphia (PA): Mosby Elsevier.
40. Yang Y, Leggat D, Herbert A, Roberts PC, Sundick RS. 2009. A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particles. J Interferon Cytokine Res 29(1):9-22.
41. Yao YX, Li W, Kaplan MH, Chang CH. 2005. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med 201(12):1899-1903. (Pubitemid 41002926)